Form 4: Blueprint Medicines Director Alexis Borisy Receives Stock Grants and Options

Director Alexis Borisy received restricted stock units and stock options from Blueprint Medicines Corp on June 12, 2024.

Summary

• On June 12, 2024, Alexis Borisy, a director of Blueprint Medicines Corp, received 2,242 restricted stock units and an option to purchase 4,570 shares of common stock.
• The restricted stock units vest on the earlier of June 12, 2025, or the date of the next annual meeting of the Issuer's stockholders.
• Each restricted stock unit represents a contingent right to receive one share of Blueprint Medicines' common stock.
• The stock option, with an exercise price of $106.14, also vests on the earlier of June 12, 2025, or the date of the next annual meeting of the Issuer's stockholders and expires on June 12, 2034.
• Following these transactions, Borisy directly owns 74,160 shares of Blueprint Medicines' common stock and options to purchase 4,570 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company's success.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock grants and options are common forms of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedules are typical, often tied to continued service or performance milestones.
• Comparable companies like Vertex Pharmaceuticals or Amgen also utilize stock options and restricted stock units as part of their executive compensation plans.

Stakeholder Impact

• The stock grants and options could potentially increase shareholder value if the company performs well.
• The grants incentivize the director to work towards the company's success, benefiting employees and other stakeholders.

Key Dates